The nationwide sales training programs conducted during the previous quarters have concluded and are expected to give our sales force new products to add to our superior service model. вЂњThe resiliency of our workforce and the strength of our relationships has driven our continued growth during these unprecedented times. вЂњWe are excited to report another record breaking quarter despite headwinds associated with the Delta variant,вЂќ said Casey Hoyt, Viemed's CEO. Total net revenues for the fourth quarter of 2021 are estimated to be approximately $29.3 million to $30.5 million.

While the Company's COVID-19 response related business has slowed during the current year, the Company is continuing to pursue additional sales and support revenues and estimates fourth quarter 2021 net revenues of approximately $1.5 million to $1.7 million related to the COVID-19 pandemic. The Company expects to generate net revenues attributable to its core business of approximately $27.8 million to $28.8 million during the fourth quarter of 2021.The Company grew its ventilator patient count to 8,200 at September 30, 2021, compared to 8,103 at June 30, 2021.Long-term debt as of Septemwas $4.3 million ($5.8 million at December 31, 2020). The Company had a cash balance of $26.9 million at Septem($31.0 million at December 31, 2020) and an overall working capital balance of $27.2 million at Septem($24.2 million at December 31, 2020).GAAP financial measures can be found in the tables accompanying this press release. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. Adjusted EBITDA for the quarter ended Septemtotaled $7.4 million and Adjusted EBITDA for the nine months ended Septemtotaled $19.7 million.In the prior year comparable period, net income included an income tax benefit of $5.3В million and $29.3 million of COVID-19 response sales and services during the height of the COVID-19 pandemic. Net income for the nine months ended Septemtotaled $5.0 million, compared to $26.5 million for the nine months ended September 30, 2020. Net income for the quarter ended Septemtotaled $1.8 million, compared to $2.8В million for the quarter ended September 30, 2020.Net revenues attributable to the core business were up approximately 6% from the second quarter of 2021.

Net revenues attributable to the Company's core business for the quarter ended Septemwere $27.8 million, a new Company record, and an increase of $2.9 million, or 12%, over core business revenues reported for the comparable quarter ended September 30, 2020.

Total net revenues for the current quarter were $29.3 million and included $1.5 million of net revenues for contact and vaccine tracing services and product sales related to the COVID-19 pandemic.

Operational highlights (all dollar amounts are USD): (the вЂњCompanyвЂќ or вЂњViemedвЂќ) (NASDAQ:VMD and TSX: VMD.TO), a home medical equipment supplier and the nationвЂ™s largest independent provider of ventilation that provides post-acute respiratory care services, today reported its financial results for the three and nine months ended September 30, 2021. 01, 2021 (GLOBE NEWSWIRE) - Viemed Healthcare, Inc.

Vmd healthcare training